Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold A Systematic Review and Meta-Analysis by Lipinski, Michael J. et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 1 , 2 0 1 6
ª 2 0 1 6 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 5 . 0 9 . 0 2 4Scaffold Thrombosis After Percutaneous
Coronary Intervention With ABSORB
Bioresorbable Vascular Scaffold
A Systematic Review and Meta-AnalysisMichael J. Lipinski, MD, PHD, Ricardo O. Escarcega, MD, Nevin C. Baker, DO, Hadiya A. Benn,
Michael A. Gaglia, JR, MD, MSC, Rebecca Torguson, MPH, Ron Waksman, MDABSTRACTFro
rep
MaOBJECTIVES The aim of this study was to determine the risk of scaffold thrombosis (ST) after percutaneous coronary
intervention (PCI) with placement of an ABSORB bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara,
California) by conducting a systematic review and meta-analysis.
BACKGROUND PCI with BVS placement holds great potential, but concern has recently been raised regarding the
risk of ST.
METHODS MEDLINE/PubMed, Cochrane CENTRAL, and meeting abstracts were searched for all studies that included
outcomes data for patients after PCI with BVS placement. For studies comparing BVSs with drug-eluting stents (DES),
pooled estimates of outcomes, presented as odds ratios (ORs) with 95% conﬁdence intervals (CIs), were generated with
random-effects models.
RESULTS Our analysis included 10,510 patients (8,351 with a BVS and 2,159 with DES) with a follow-up of 6.4
 5.1 months and 60  11 years of age; 78% were male, 36% had stable angina, and 59% had acute coronary syndrome
(ACS). Among patients with a BVS, cardiovascular death occurred in 0.6%, myocardial infarction (MI) in 2.1%, target
lesion revascularization in 2.0%, and deﬁnite/probable ST in 1.2% of patients. Of BVS patients, 0.27% had acute ST and
0.57% had subacute ST. Meta-analysis demonstrated that patients who received a BVS were at a higher risk of MI (OR:
2.06, 95% CI: 1.31 to 3.22, p ¼ 0.002) and deﬁnite/probable ST (OR: 2.06, 95% CI: 1.07 to 3.98, p ¼ 0.03) compared
with patients who received DES, whereas there was a trend toward decreased all-cause mortality with a BVS (OR: 0.40,
95% CI: 0.15 to 1.06, p ¼ 0.06).
CONCLUSIONS Patients undergoing PCI with a BVS had increased deﬁnite/probable ST and MI during follow-up
compared with DES. Further studies with long-term follow-up are needed to assess the risk of ST with a BVS.
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13degradation over the course of 3 to 4 years (3,4) neces-
sitate adequate dual antiplatelet therapy for at least
12 months.SEE PAGE 25
ACS = acute coronary
syndrome(s)
BVS = bioresorbable vascular
scaffold
CI = conﬁdence interval
DES = drug-eluting stent(s)
MACE = major adverse
cardiovascular event(s)
MI = myocardial infarction
OR = odds ratio
PCI = percutaneous coronary
intervention
ST = scaffold thrombosis
STEMI = ST-segment elevation
myocardial infarctionSince the ABSORB BVS (Abbott Vascular, Santa
Clara, California) gained the CEMark, the ABSORB BVS
has been used in the treatment of increasingly com-
plex patients. The initial ABSORB studies predomi-
nantly treated patients with stable angina and stressed
the importance of vessel preparation (5,6). Although
studies are under way to assess BVSs in patients with
acute coronary syndrome (ACS), initial registry data,
namely, the GHOST-EU (Gauging coronary Healing
with biOresorbable Scaffolding plaTforms in EUrope)
and AMC (Academic Medical Center) registries (7,8),
had alarmingly high rates of ST. Given the increased
risk of ST after PCI for patients with ACS, especially
after ST-segment elevation myocardial infarction
(STEMI) (9), it is not surprising that the risk of STwith a
BVS also increases in the hypercoagulable setting of
ACS, given the greater strut thickness and higher risk
of malapposition due to undersizing. Thus, concern
has been raised regarding the safety of BVSs with re-
gard to ST, particularly in the setting of ACS (10,11).
Thus, we performed a systematic review and meta-
analysis to assess the incidence of ST and other car-
diovascular outcomes after PCI with placement of the
ABSORB BVS and compare outcomes with patients
who received DES.
METHODS
Two independent reviewers (MJL and HAB) sys-
tematically searched (July 2015) MEDLINE/PubMed
and available abstract data, applying the search
terms “bioresorbable” AND “scaffold”. We limited
our data to studies using the ABSORB BVS. We also
obtained presentation slides of the late breaking
clinical trials (including Euro PCR 2015 meeting). We
included studies in human patients: 1) that under-
went PCI for obstructive coronary artery disease;
2) with at least 1 month clinical follow-up data; and
3) included patients who underwent placement of the
ABSORB BVS. We excluded studies with inadequate
data for abstraction, duplication of data, case reports
and case series, studies using other bioresorbable
scaffolds (polymer or metallic), and studies using
metallic stents with bioresorbable polymer coating.
Data were abstracted by the same 2 investigators
(M.J.L. and H.A.B.) in accordance with PRISMA
(Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) guidelines (12). When available,
we abstracted clinical data in studies comparingclinical outcomes of BVSs and DES, which
predominantly used everolimus-eluting per-
manent metallic stents. As demonstrated
in our comprehensive search, the data
comparing BVSs with DES was limited
compared with a large number of studies
assessing outcomes of BVS patients alone
(prospective registry data and retrospective
series). In addition to study, patient, and
lesion characteristics, we collected outcome
data for cardiovascular death, death, major
adverse cardiovascular events (MACE),
myocardial infarction (MI), target vessel
revascularization, target lesion revasculari-
zation, deﬁnite or probable ST, deﬁnite ST,
acute ST, subacute ST, and late ST. The
longest available follow-up was used when
available. Deﬁnitions for ST were consistent
with Academic Research Consortium criteria (13).
DATA SYNTHESIS AND ANALYSIS. Dichotomous
variables are reported as proportions (percentages),
and continuous variables are reported as mean  SD or
median (interquartile range). For studies comparing
BVSs and DES, binary outcomes from individual
studies were combined with random-effects models,
leading to computations of odds ratios (ORs) with 95%
conﬁdence intervals (CIs). I2 was calculated as a mea-
sure of statistical heterogeneity; I2 values of 25%, 50%,
and 75% represented mild, moderate, and severe
inconsistency, respectively. Small study or publication
bias was explored with funnel plots and the Peters
test (14). To combine data to compare between the
groups, we generated weighted means for all variables
with pooled SDs (15). This enables comparison
between the weighted means because 95% CIs for the
weighted means can be generated through conversion
of the pooled SD into the pooled SE of the mean. Meta-
regression analysis was performed to assess the cor-
relation of certain variables with certain outcomes.
Statistical analysis was performed with NCSS Statisti-
cal System 2007 (Kaysville, Utah) and GraphPad
Prism 6 (La Jolla, California). A meta-analysis was
performed using Review Manager (RevMan) 5 version
5.3 freeware package (The Nordic Cochrane Centre,
The Cochrane Collaboration, Copenhagen, Denmark,
2008) and Comprehensive Meta-Analysis version 3
(trial version). Statistical signiﬁcance for hypothesis
testing was set at the 0.05 two-tailed level and for
heterogeneity testing at the 0.10 two-tailed level.
RESULTS
Using PubMed, Cochrane CENTRAL, and available
abstract data, we applied the following search term
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14“bioresorbable” AND “scaffold” and identiﬁed 449
citations. Implementing our inclusion/exclusion cri-
teria deﬁned in the Methods section, we evaluated 88
abstracts, of which we assessed 54 as full-text publi-
cations or as abstract slides presented at national
meetings. We excluded studies due to duplication of
data (4,16–20), case reports, case series, less than
1 month follow-up data (21), inadequate data (22), and
studies that did not include the ABSORB BVS. Our
search ﬂow diagram is shown in Figure 1. The 25
studies from 26 publications in our systematic review
and meta-analysis (6–8,23–45) included 10,510 pa-
tients with a mean follow-up of 6.4  5.1 months. In
these studies, 8,351 patients received the ABSORB
BVS with an average of 1.22  0.16 lesions per pa-
tients, whereas 2,159 patients received metallic DES.
Baseline study characteristics are shown in Table 1,
baseline patient characteristics are shown in Table 2,
and lesion characteristics for lesions treated with a
BVS are shown in Table 3. The patients included in
our study had a pooled mean  SD age of 60  11
years, 78% were male, 18% had a previous MI, 64%
had hypertension, 59% had hyperlipidemia, 22% had
diabetes mellitus, and 40% were current smokers. PCI
for stable angina was performed in 36% of patients,
and 59% underwent PCI for ACS (14% for unstable
angina, 18% for non-STEMI, and 27% for STEMI).
From the available study-level data, the lesion
treated involved the left anterior descending artery inFIGURE 1 Study Flow Chart
Study selection process for the systematic review and meta-
analysis.53%, the left circumﬂex artery in 28%, and the right
coronary artery in 32%. A BVS tended to be deployed
in more complex lesions, with only 16% of lesions
being American Heart Association/American College
of Cardiology class A, 37% of lesions were class B1,
28% of lesions were class B2, and 19% of lesions were
class C. There was a high use of pre-dilation at 91%,
and post-dilation was used in 52% of lesions after BVS
deployment. The mean  SD lesion length was 17  10
mm and the mean  SD total scaffold length was 26
 15 mm. However, scaffold and lesion length varied
more because studies assessing BVSs for patients with
chronic total occlusion used a greater total length of
BVSs (31,44). Angiographic measurements of the
lesions before and after treatment with BVSs are
shown in Table 3.
A summary of the study-level outcomes is shown
in Table 4. Among the 8,183 patients who received a
BVS, death occurred in 0.8% of patients, cardiovas-
cular death in 0.6% of patients, MACE in 4.1% of
patients, MI in 2.1% of patients, target vessel revas-
cularization in 2.7% of patients, target lesion revas-
cularization in 2.0% of patients, and deﬁnite or
probable ST in 1.2% of patients.
SCAFFOLD THROMBOSIS. Given the variable dura-
tion of follow-up, we focused on deﬁnite or probable
ST at 1 month as 1 month follow-up was available for
most of the studies included. Among patients after
BVS implantation in which acute and subacute ST was
reported, the risk of acute ST was 0.27% and the risk
of subacute ST was 0.57%. Early discontinuation of
dual antiplatelet therapy was only associated with
22% of ST cases. Studies with a higher percentage of
patients undergoing PCI for ACS with either a BVS or
DES had a trend toward an increased risk of ST during
follow-up (Figure 2). Importantly, at the study level,
there was no association between the percentage of
patients receiving pre-dilation (R2 ¼ 0.01; p ¼ 0.63) or
post-dilation (R2 ¼ 0.03; p ¼ 0.43) and the risk of ST at
1 month. We next performed correlation analysis and
demonstrated that the incidence of ST at 1 month and
during long-term follow-up increased over time but
not to a signiﬁcant degree (Figure 3). This may reﬂect
an increase in the studies using a BVS in patients with
ACS. Interestingly, it is worth mentioning a series by
Azzalini and L’Allier (22), although not included in
our analysis due to lack of adequate patient data, that
reported an incidence of 1.2% for deﬁnite ST with 4 of
339 patient all-comers who received a total of 504
BVSs at their institution.
META-ANALYSIS. Nine studies provided data com-
paring outcomes in patients with a BVS and DES
(23,24,27,29,32,35,38,40,43). Among the 9 included
TABLE 1 Study Characteristics
Study First Author (Ref. #)
Beginning of
Enrollment Year Study Type
Follow-Up
(Months)
Patients Lesions
BVS DES BVS DES
ABSORB Ormiston et al. (6) Mar 2009 2012 Prospective 24 101 NA NR NA
ABSORB II Serruys et al. (23) Nov 2011 2015 Prospective RCT 12 335 166 364 182
ABSORB EXTEND Abizaid et al. (24) Jan 2010 2015 Prospective registry with
propensity matched
data from Xience V
12 812 812 874 NR
ABSORB FIRST Eeckhout et al. (25) Jan 2013 2015 Prospective registry 12 958 NA 1,188 NA
AMC Kraak et al. (8) Aug 2012 2014 Prospective registry 6 135 NA 159 NA
ASSURE Wohrle et al. (26) Apr 2012 2014 Prospective registry 12 183 NA 198 NA
BVS-EXAMINATION Brugaletta et al. (27) Dec 2012 2015 Prospective study with
propensity-matched
data from Xience V
12 290 290 NR NR
BVS EXPAND van Geuns (28) Sept 2012 2014 Prospective registry 6 200 NA 275 NA
BVS-RAI Cortese et al. (29) Dec 2012 2015 Prospective registry Up to 12 122 135 441 470
BVS STEMI Diletti et al. (30) Nov 2012 2014 Prospective 1 49 NA NR NA
CTO-ABSORB Vaquerizo et al. (31) Feb 2013 2014 Prospective registry 6 35 NA NR NA
EVERBIO II Puricel et al. (32) Nov 2012 2015 Prospective RCT 9 78 160 101 224
GABI-R Hamm (33) Nov 2013 2015 Prospective registry 1 1,536 NA 2,018 NA
GHOST-EU Capodanno et al. (7) Nov 2011 2014 Prospective registry 6 1,189 NA 1,440 NA
POLAR-ACS Dudek et al. (34) Nov 2012 2014 Prospective registry 12 100 NA 100 NA
PRAGUE-19 Kocka et al. (35) Dec 2012 2014 Prospective 6 40 57* 40 57
REPARA Hernandez (36) Jan 2014 2015 Prospective registry 1 1,627 NA 2,195 NA
Robaei et al. (37) Dec 2010 2015 Prospective registry 1 100 NA 152 NA
Costopoulos et al. (38) Oct 2007 2015 Retrospective
propensity analysis
6 92 92 137 124
Gori et al. (39,40) May 2012 2014 Retrospective 1 for comparison/
median of 12
for BVS alone
150 103 194 129
Jaguszewski et al. (41) Sept 2012 2014 Retrospective Mean, 4.9 106 NA 139 NA
Kajiya et al. (42) Oct 2012 2013 Retrospective Median, 1.8 11 NA 11 NA
Mattesini et al. (43) Sept 2012 2014 Retrospective Mean, 8.5 for BVS
and 17.3 for DES
35 38 50 50
Ojeda et al. (44) Feb 2013 2015 Retrospective Mean, 13 42 NA 46 NA
Wiebe et al. (45) Oct 2012 2014 Retrospective Median, 4.6 25 NA 31 NA
*Comparison group included bare metal stents.
BVS ¼ bioresorbable vascular scaffold; DES ¼ drug-eluting metallic stent(s); NA ¼ not applicable; NR ¼ not reported; RCT ¼ randomized, controlled trial.
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15studies, outcomes data were available for 1,948 pa-
tients who received a BVS and 2,150 patients who
received DES. The characteristics of these patients are
shown in Online Table 1. As seen in Figure 4, there
was no signiﬁcant difference between cardiovascular
death (OR: 0.81, 95% CI: 0.42 to 1.58; p ¼ 0.54) or
MACE (OR: 0.87, 95% CI: 0.66 to 1.16; p ¼ 0.35).
Although not signiﬁcant, there was a trend toward
less all-cause mortality with a BVS compared with
DES (OR: 0.40, 95% CI: 0.15 to 1.06; p ¼ 0.06). How-
ever, the placement of BVS was associated with
increased risk of MI during follow-up compared
with placement of DES (OR: 2.06, 95% CI: 1.31 to 3.22],
I2 ¼ 0%; p ¼ 0.002) (Figure 5). There was no signiﬁcant
difference in target lesion revascularization (OR:
0.87, 95% CI: 0.59 to 1.28; p ¼ 0.47) or target vessel
revascularization (OR: 0.77, 95% CI: 0.48 to 1.25;
p ¼ 0.29) after placement of a BVS compared with
placement of DES (Figure 5). Importantly, as seen inFigure 6, deﬁnite or probable ST was signiﬁcantly
increased after placement of a BVS compared with
DES (OR: 2.06, 95% CI: 1.07 to 3.98, I2 ¼ 0%; p ¼ 0.03)
with a trend toward an increase in deﬁnite ST
(OR: 1.91, 95% CI: 0.82 to 4.46; p ¼ 0.13) and ST at
1 month (OR: 2.02, 95% CI: 0.69 to 5.93; p ¼ 0.20).
Among the included analyses, there was low hetero-
geneity as assessed by I2. Visual inspection of funnel
plot analysis along with the Peters test did not
demonstrate signiﬁcant publication bias for the out-
comes assessed in our meta-analysis. Similar ﬁndings
were also noted between the randomized and non-
randomized, controlled trials (Figures 4 to 6). When
limiting the analysis to studies with 12 months of
follow-up, a BVS was still associated with a signiﬁcant
increase in MI (OR: 2.23, 95% CI: 1.35 to 3.68; p ¼
0.002) and deﬁnite or probable ST (OR: 2.29, 95% CI:
1.06 to 4.94; p ¼ 0.03) compared with DES (Online
Figure 1).
TABLE 2 Patient Characteristics of All Patients Included in the Studies
Study/First Author n
Age,
yrs
Male,
%
HTN,
%
HLD,
%
Diabetes,
%
Current Smoker,
%
Previous MI,
%
SA,
%
ACS,
%
UA,
%
NSTEMI,
%
STEMI,
%
ABSORB 101 62  9 72 62 78 17 17 25 69 27 27 0 0
ABSORB II 501 61  10 77 70 77 24 23 28 64 21 21 0 0
ABSORB EXTEND 812 61 74 69 68 27 23 29 73 27 27 0 0
ABSORB FIRST 958 59  11 80 64 65 24 34 18 28 54 15 39 NR
AMC 135 59  11 73 50 43 20 29 25 47 50 10 27 13
ASSURE 183 64  9 80 82 76 26 NR 27 36 NR 21 NR NR
BVS-EXAMINATION 580 57  12 81 47 44 13 NR 3 0 100 0 0 100
BVS EXPAND 200 61 75 58 51 19 58 18 NR NR NR NR NR
BVS-RAI 563 59 (52–67) 78 58 59 18 45 7 0 100 0 0 100
BVS STEMI 49 59  11 78 39 22 8 69 2 0 100 0 0 100
CTO-ABSORB 35 61  10 80 60 74 20 20 29 71 NR NR NR 0
EVERBIO II 238 65  11 79 61 61 23 35 17 48 39 8 21 10
GABI-R 1,536 62  11 77 76 60 21 57 NR NR 50 12 22 16
GHOST-EU 1,189 62  11 79 74 53 25 30 NR 53 47 13 18 16
POLAR-ACS 100 63  10 73 78 72 27 44 16 0 100 46 38 16
PRAGUE-19 97 62  12 76 NR NR 15 60 8 0 100 0 0 100
REPARA 1,627 57  11 81 52 55 24 48 NR 18 78 18 27 33
Robaei et al. 100 62  12 68 74 71 19 13 15 56 44 25 15 4
Costopoulos et al. 184 63  11 87 66 65 28 15 32 89 11 NR NR NR
Gori et al. 253 62  12 72 66 38 17 55 12 0 100 17 42 41
Jaguszewski et al. 106 61  11 76 44 53 20 32 15 58 42 NR NR 17
Kajiya et al. 11 50  11 82 36 55 27 55 NR 0 100 0 0 100
Mattesini et al. 73 63  11 79 67 66 31 42 15 96 4 4 0 0
Ojeda et al. 42 58  9 98 57 64 33 19 28 100 0 0 0 0
Wiebe et al. 25 57  11 76 84 36 20 NR NR 0 100 0 0 100
Weighted mean 368 60  11 78 64 59 22 40 18 36 59 14 18 27
Values are mean  SD or median (interquartile range) unless otherwise indicated.
ACS ¼ acute coronary syndrome(s); HLD ¼ hyperlipidemia; HTN ¼ hypertension; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial infarction; SA ¼ stable angina; STEMI ¼ ST-
segment elevation myocardial infarction; UA ¼ unstable angina.
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16Meta-regression analysis was then performed to
assess the impact of the percentage of patients with
ACS or STEMI in the included studies on the out-
comes of deﬁnite or probable ST and MI when
comparing a BVS and DES. Meta-regression analysis
did not demonstrate that the percentage of patients
with ACS at the study level had an impact on ST
(p ¼ 0.15) or MI (p ¼ 0.26) with a BVS compared with
DES. Furthermore, there was not a study-level corre-
lation between the percentage of patients with
STEMI and either ST (p ¼ 0.17) or MI (p ¼ 0.61) during
follow-up.
DISCUSSION
Our systematic review and meta-analysis included
all available outcomes data for patients treated with
PCI and placement of a BVS. The data demonstrated
that patients treated with a BVS had a incidence of
cardiovascular death, MACE, target lesion revascu-
larization, and target vessel revascularization com-
parable to that in patients who received DES.However, patients treated with a BVS did have a
signiﬁcantly higher incidence of MI and deﬁnite/
probable ST during follow-up with a 2-fold increase
but a trend toward less all-cause mortality. Patients
who received a BVS appeared to have a typical dis-
tribution of cardiovascular risk factors and lesion
complexity as with patients undergoing PCI. Although
rates of cardiovascular death, MACE, and target lesion
revascularization after BVS placement appear typical
after PCI, the risk of ST at 1 month was 0.84%. While
this risk may be high for patients undergoing elective
PCI for stable angina, it is important to note that a
recent meta-analysis of randomized trials in patients
undergoing primary PCI for STEMI that predomi-
nantly used DES demonstrated 115 episodes of deﬁnite
ST at 1 month among 8,156 patients, for an incidence
of 1.4% (9). Thus, it is not surprising that our study
showed a trend toward an increased incidence of
deﬁnite/probable ST for both BVSs and DES for
studies with a greater proportion of ACS patients.
The incidence of ST among patients with DES in our
meta-analysis was also fairly low, consistent with
TABLE 3 Lesion and Procedural Characteristics for Lesions Treated With a BVS
Study
AHA/ACC Lesion Class, %
LAD, % LCX, % RCA, %
Total Scaffold
Length, mm Lesion Length, mm Pre-BA, % Post-BA,% Baseline RVD Baseline MLD Baseline %DS Post In-Scaffold MLD Post % DSA B1 B2 C
ABSORB 1 55 40 4 43 24 34 12  0 9.9  3.6 100 NR 2.61  0.37 1.06  0.28 59  10 2.27  0.26 15  6
ABSORB II 1 53 44 2 45 29 26 21.1  8.8 13.8  6.5 100 61 2.59  0.38 1.07  0.32 59  11 2.22  0.33 16  7
ABSORB EXTEND 2 53 42 3 45 26 28 NR 12.3  5.3 NR NR 2.65  0.39 1.11  0.32 58 NR NR
ABSORB FIRST 17 35 23 24 51 21 28 NR 18.5  9.3 94 47 3.05  0.45 0.58  0.44 81  13.6 NR 2.2  6.3
AMC 17 16 42 25 60 15 23 NR NR 98 55 2.34  0.67 0.79  0.46 68  18 2.16  0.42 18  7
ASSURE 13 22 43 21 42 22 24 NR 11.6 (9.3–16.5) 99 13 2.6  0.5 0.9  0.5 64.6  15.1 2.5  0.4 16.1  7.7
BVS-EXAMINATION NR NR NR NR 45 13 41 22.2  9.0 NR 81 36.3 NR NR NR NR NR
BVS EXPAND NR NR NR NR NR NR NR NR 25.4  13.5 92 47 NR NR NR NR 17.5  8.45
BVS-RAI NR NR NR NR 61 13 27 18 (18,28) NR 94 94 NR NR 99 NR NR
BVS STEMI NR NR NR NR 43 12 45 26.4  13.9 NR 67 20 2.78  0.70 0.38  0.31 85.4  8.8 2.44  0.49 14.7  8.2
CTO-ABSORB 0 0 0 100 40 11 46 52.5  23.0 35.9  15.8 100 63 2.99  0.34 0  0 100 2.41  0.38 13.9  3.6
EVERBIO II 20 51 14 16 46 25 25 22.8  8.8 NR 97 34 2.77  0.60 0.60  0.58 81.3  16.2 2.56  0.43 9.3  5.7
GABI-R 21.9 37.6 22.5 18 68 45 50 27.6  17.0 NR 93 67 NR NR NR NR NR
GHOST-EU 22 27 24 28 47 25 25 32.6  23.0 19.4  14.4 98 49 3.0  0.5 NR NR NR NR
POLAR-ACS 6 33 40 21 48 27 21 23.4  11.0 15.6  5.9 93 75 2.8  0.5 NR 65.6  17.6 2.3  0.4 13.1  8.47
PRAGUE-19 NR NR NR NR 40 23 37 23.7  12.0 NR 85 33 2.80  0.38 NR NR 2.78  0.29 NR
REPARA 19.2 38.7 26.6 14.7 51 22 27 23.0  13.3 NR 78 40 NR NR NR NR NR
Robaei et al. 10 34 19 37 42 13 42 22.7 20.9  13.0 100 95 2.8  0.5 0.89  0.59 79.48  11.3 NR NR
Costopoulos et al. NR NR NR NR 63 23 13 NR NR 98 99 NR NR NR NR NR
Gori et al. NR NR NR NR 42 19 38 19.4  4.6 NR 100 14 NR NR NR NR NR
Jaguszewski et al. 24 34 24 17 NR NR NR NR NR NR NR NR NR NR NR NR
Kajiya et al. NR NR NR NR 64 18 18 NR NR NR 91 NR NR NR NR NR
Mattesini et al. 0 0 36 64 68 8 22 NR 24.7  14.2 100 100 2.7  0.4 0.8  0.4 NR 2.7  0.4 NR
Ojeda et al. 0 0 0 100 48 24 28 43  21 35  19 100 100 3.03  0.4 0  0 100 2.7  0.4 11  6
Wiebe et al. NR NR NR NR 48 36 16 NR NR NR 13% NR NR NR NR NR
Weighted mean 16 37 28 19 53 28 32 26  15 17  10 91 52 2.84  0.46 0.83  0.39 71  13 2.36  0.37 10  7
Values are mean  SD or median (interquartile range) unless otherwise indicated.
ACC/AHA ¼ American College of Cardiology/American Heart Association; BA ¼ balloon angioplasty; %DS ¼ percentage diameter stenosis; LAD ¼ left anterior descending coronary artery; LCX ¼ left circumﬂex coronary artery; MLD ¼ minimal luminal diameter;
NR ¼ not reported; RCA ¼ right coronary artery; RVD ¼ reference vessel diameter.
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TABLE 4 Patient Outcomes
Study BVS Death CVD MACE MI TVR TLR Def ST D/P ST A/S/L ST No DAPT ST DES Death CVD MACE MI TVR TLR Def ST D/P ST A/S/L ST
ABSORB 100 0 0 9 3 6 6 0 0 0 0
ABSORB II 329 0 0 24 15 8 4 2 3 1/1/1 0 164 1 0 15 2 8 3 0 0 0
ABSORB EXTEND 812 NR 6 41 27 NR 19 NR 8 NR NR 812 NR 5 39 12 NR 24 0 2 NR
ABSORB FIRST 958 12 5 25 17 NR 13 NR 8 0/4/4 NR
AMC 134 1 1 11 4 11 8 4 4 0/3/1 2
ASSURE 183 2 1 9 3 9 5 0 0 0 0
BVS-EXAMINATION 290 NR 6 NR 6 NR 5 5 7 NR/6/1 1 290 NR 6 NR 4 NR 4 2 4 NR/1/3
BVS EXPAND 180 4/200 3/200 6 3 4 4 4 4 NR NR
BVS-RAI 122 1 0 6 5 5 5 3 3 NR NR 441 9 7 32 9 23 20 6 6 NR
BVS STEMI 49 0 0 1 1 0 0 0 0 0 0
CTO-ABSORB 35 0 0 0 0 0 0 0 0 0 0
EVERBIO II 78 1 1 9 1 8 6 0 1 0/0/1 0 160 3 0 15 1 13 9 0 0 0
GABI-R 1,536 5 2 28 22 14 NR NR 15 7/8 3
GHOST 1,189 13 10 NR 21 NR 25 20 23 5/11/7 3
POLAR-ACS 98 0 0 4 3 2 2 1 1 0/1/0 1
PRAGUE-19 40 0 0 2 2 1 1 1 1 0/1/0 1 57 1 1 4 1 2 2 0 0 0
REPARA 1,479 NR 5 NR 23 NR 12 NR 13 3/10 4
Robaei et al. 99 0 0 4 4 0 0 0 0 0 0
Costopoulos et al. 92 0 0 3 0 3 3 0 0 0 0 92 2 1 7 0 6 5 0 0 0
Gori et al. 150 2 2 16 6 3 3 3 4 1/3 0 103 3 3 16 4 2 2 2 3 1/2
Gori et al.* 133 4 4 18 9 14 9 3 4 1/3/0 0
Jaguszewski et al. 98 2 1 6 3 2 2 2 2 1/1/0 0
Kajiya et al. 11 1 1 1 0 0 0 0 0 0 0
Mattesini et al. 35 0 0 2 1 2 1 0 0 0 0 31 0 0 0 0 2 2 0 0 0
Ojeda et al. 42 0 0 2 1 2 2 0 0 0 0
Wiebe et al. 24 1 1 2 1 0 0 0 0 0 0
*Updated outcomes data with 12-month follow-up but limited to patients who received a BVS. The value in the table represents the number of patients and the number of patients that had the speciﬁed event for each study.
A/S/L ST ¼ acute/subacute/late scaffold thrombosis; BVS ¼ bioresorbable vascular scaffold; CVD ¼ cardiovascular death; DAPT ¼ dual antiplatelet therapy; Def ST ¼ deﬁnite scaffold thrombosis; D/P ST ¼ deﬁnite or probable scaffold thrombosis; MACE ¼ major
adverse cardiovascular event(s); TLR ¼ target lesion revascularization; TVR ¼ target vessel revascularization.
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FIGURE 2 Scaffold Thrombosis and Percentage of Patients
With ACS
Correlation between deﬁnite/probable scaffold thrombosis and
the percentage of patients with ACS among included studies in
patients with BVS (top) and DES (bottom) with weighting of
studies based on the number of patients. ACS ¼ acute coronary
syndrome(s); BVS¼ bioresorbable vascular scaffold; DES ¼ drug-
eluting stent(s).
FIGURE 3 Scaffold Thrombosis and Date of Study Initiation
Correlation between the percentage of deﬁnite/probable scaf-
fold thrombosis at 1 month (top) and longest follow-up
(bottom) with the time of enrollment initiation with weighting of
studies based on the number of patients.
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19the current incidence previously cited. While our
meta-analysis showed an increased incidence of ST
with BVSs compared with DES, this ﬁnding should be
viewed as hypothesis generating as much of the data
were generated from propensity-matched and retro-
spective studies. Further prospective, randomized,
controlled trials, especially in patients with ACS, will
be very helpful in assessing whether patients under-
going PCI are at increased risk of ST after BVS place-
ment compared with DES.
Understanding the potential mechanisms under-
lying ST after BVS deployment is critical (10). Inter-
estingly, strut thickness does not appear to play a
role. A recent propensity-matched analysis found
that the risk of periprocedural MI was increased with
a BVS compared with ﬁrst-generation DES (46), whichhave a comparable strut thickness. Thus, the strut
thickness does not appear to account for the
increased risk of periprocedural MI. In a case series of
14 patients presenting with deﬁnite BVS thrombosis,
4 of 14 patients showed incomplete lesion coverage
by angiography (47). Optical coherence tomography
was performed in 9 patients and demonstrated mal-
apposition in 5 of them, strut discontinuity in 2, and
underexpansion in 2 (47). Importantly, 5 of 14 cases
BVS thrombosis occurred after dual antiplatelet
therapy discontinuation. Thus, BVSs may need to be
avoided in individuals requiring PCI where there is
concern regarding medication compliance. Very late
ST is potentially a risk due to heterogeneous endo-
thelialization of the scaffold struts (48) or failure of
degradation due to incomplete integration into the
vascular wall (49). This may help account for the
delay and heterogeneity of degradation previously
seen with BVSs (3). Late scaffold recoil has also been
FIGURE 4 Forest Plots Comparing Death, CV Death, and MACE for BVS and DES
Forrest plots comparing all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events during follow-up for patients
who received a BVS compared with patients who received DES. Studies were divided into subgroups based on whether they were a randomized,
controlled trial (RCT) or nonrandomized, controlled trials (non-RCT). CI ¼ conﬁdence interval; M-H ¼ Mantel-Haenszel test.
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FIGURE 5 Forest Plots Comparing MI, TLR, TVR for BVS and DES
Forrest plots comparing myocardial infarction, target lesion revascularization, and target vessel revascularization during follow-up for patients
who received BVS compared with patients who received DES. Studies were divided into subgroups based on whether they were a randomized,
controlled trials (RCT) or non-randomized controlled trials (non-RCT). Abbreviations as in Figure 4.
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FIGURE 6 Forest Plots Comparing BVS and DES Scaffold Thrombosis
Forrest plots comparing deﬁnite/probable scaffold thrombosis, deﬁnite scaffold thrombosis, and 1 month (acute and subacute) scaffold throm-
bosis during follow-up for patients who received a BVS compared with patients who received DES. Studies were divided into subgroups based on
whether they were a randomized, controlled trials (RCT) or nonrandomized, controlled trials (non-RCT). Abbreviations as in Figure 4.
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PERSPECTIVES
WHAT IS KNOWN? Recent studies have raised concern
regarding the risk of ST after PCI and implantation of the
ABSORB BVS.
WHAT IS NEW? The systematic review and meta-analysis
demonstrated that the ABSORB BVS is associated with a 2-fold
increase in MI and ST compared with DES.
WHAT IS NEXT? Further randomized, controlled trials, espe-
cially in patients with ACS, are needed to assess the risk of ST
after PCI.
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23identiﬁed as a mechanism of very late ST (50). Further
large randomized, controlled trials are necessary to
assess the risk of late and very ST given the limited
data available. Techniques to reduce ST such as
intravascular ultrasound and optical coherence
tomography to demonstrate apposition need to be
studied prospectively. Finally, improvements in BVS
technology will perhaps lead to the development of
thinner struts that can prevent vessel recoil while
leading to improved strut apposition and endothelial
coverage.
STUDY LIMITATIONS. Limitations of this systematic
review and meta-analysis include the heterogeneity
of study types with very few randomized, controlled
trials. There are also few studies that compared BVSs
with DES. Further randomized, controlled trials
comparing BVSs with DES will be necessary to
determine a more accurate risk of ST in patients un-
dergoing PCI. Additionally, long-term follow-up
longer than 1 year was extremely limited in this
analysis, which reﬂects the lack of these data in the
published literature. Access to patient-level data
would greatly strengthen this analysis and enable
multivariate analysis to determine which variables
are signiﬁcantly associated with ST. In addition,
because of the variable duration of follow-up among
the studies, it was therefore difﬁcult to assess the risk
of late ST. Although random-effects pooling reduces
heterogeneity, another limitation of this meta-
analysis is the heterogeneity observed among
studies, although this appeared to be low, and there
did not appear to be publication bias. Many of the
analyses in this study are limited given the lack of rawpatient information and should therefore be viewed
with caution and as hypothesis generating.
CONCLUSIONS
Patients who underwent PCI and placement of a BVS
had cardiovascular outcomes comparable to those of
patients who received DES but had a higher inci-
dence of MI and deﬁnite/probable ST. Further ran-
domized, controlled studies are necessary to assess
whether the risk of ST after BVS implantation is
increased compared with DES, especially in the
setting of ACS.
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